|
| 36343786 | UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways. | Cancer Lett | 2023 |
| 37126232 | Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance. | J Urol | 2023 |
| 37452329 | Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada. | BMC Urol | 2023 |
| 37185211 | 2023 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium Meeting highlights. | Can Urol Assoc J | 2023 |
| 37310909 | CUA: The voice of urologic oncology in Canada. | Can Urol Assoc J | 2023 |
| 37310907 | Updated cystic renal lesions guideline: A springboard for shared decision-making. | Can Urol Assoc J | 2023 |
| 37011303 | The importance of guidelines. | Can Urol Assoc J | 2023 |
| 37073437 | Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression. | J Pathol Clin Res | 2023 |
| 37037938 | A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. | Br J Cancer | 2023 |
| 37007631 | Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review. | Ther Adv Med Oncol | 2023 |
| 37329212 | Clinical analysis of EV-Fingerprint to predict grade group 3 and above prostate cancer and avoid prostate biopsy. | Cancer Med | 2023 |
| 36849116 | Let's not forget our residents in training. | Can Urol Assoc J | 2023 |
| 36791755 | Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk. | J Natl Compr Canc Netw | 2023 |
| 36373402 | Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer. | J Urol | 2023 |
| 36347965 | Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer. | Br J Cancer | 2023 |
| 34706850 | Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. | Clin Genitourin Cancer | 2022 |
| 35411033 | Fatty acid oxidation enzyme ο3, ο2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. | Oncogene | 2022 |
| 35623007 | Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. | Can Urol Assoc J | 2022 |
| 35621665 | The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context. | Curr Oncol | 2022 |
| 36656693 | Managing advanced prostate cancer: No longer the primary domain of general urology. | Can Urol Assoc J | 2022 |
| 36671257 | Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study. | Antibiotics (Basel) | 2022 |
| 36421333 | Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. | Curr Oncol | 2022 |
| 35905486 | Testicular cancer survivorship: Long-term toxicity and management. | Can Urol Assoc J | 2022 |
| 35905484 | UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes. | Can Urol Assoc J | 2022 |
| 35905482 | UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. | Can Urol Assoc J | 2022 |
| 35905296 | Back in the saddle: CUA's return to a live meeting was a huge success! | Can Urol Assoc J | 2022 |
| 36240331 | The CUA: Advocating for our patients. | Can Urol Assoc J | 2022 |
| 36172886 | Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. | Clin Transl Sci | 2022 |
| 36378572 | 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). | Can Urol Assoc J | 2022 |
| 34530170 | Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma. | Pract Radiat Oncol | 2022 |
| 31186173 | Multimodal Prehabilitation to Enhance Functional Capacity Following Radical Cystectomy: A Randomized Controlled Trial. | Eur Urol Focus | 2021 |
| 33828256 | Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. | Br J Cancer | 2021 |
| 33676834 | The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada. | Clin Genitourin Cancer | 2021 |
| 33556313 | 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). | Can Urol Assoc J | 2021 |
| 35099374 | Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version. | Can Urol Assoc J | 2021 |
| 35098169 | Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy. | Eur Urol Open Sci | 2021 |
| 33938798 | Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text. | Can Urol Assoc J | 2021 |
| 34127184 | Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. | Can Urol Assoc J | 2021 |
| 34127181 | Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary. | Can Urol Assoc J | 2021 |
| 33283758 | Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary? | Urol Oncol | 2021 |
| 33421558 | Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. | Int J Radiat Oncol Biol Phys | 2021 |
| 30997868 | Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. | J Oncol Pharm Pract | 2020 |
| 31793860 | The use of perioperative chemotherapy in patients undergoing radical cystectomy for bladder cancer in Quebec, Canada, 2000-2016. | Can Urol Assoc J | 2020 |
| 33259282 | When will I have my surgery? | Can Urol Assoc J | 2020 |
| 32763409 | Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples. | J Mol Diagn | 2020 |
| 33022649 | Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer. | J Natl Compr Canc Netw | 2020 |
| 32569567 | Are basic robotic surgical skills transferable from the simulator to the operating room? A randomized, prospective, educational study. | Can Urol Assoc J | 2020 |
| 32453694 | Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. | Can Urol Assoc J | 2020 |
| 32343118 | Guidance for management of cancer surgery during the COVID-19 pandemic. | Can J Surg | 2020 |
| 29623528 | A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. | Pathol Oncol Res | 2019 |